Steven Cohen Point72 Asset Management
Steven Cohen is the founder of Point72 Asset Management and previously built SAC Capital into one of the industry’s most profitable trading firms. Point72 operates a multi-manager platform combining fundamental long/short equity with systematic and other strategies. Cohen is also a major figure in sports ownership and philanthropy, while remaining one of the most closely followed names in hedge fund trading culture.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Salesforce
CRM
|
+$372M |
| 2 |
Amazon
AMZN
|
+$228M |
| 3 |
Analog Devices
ADI
|
+$121M |
| 4 |
United Therapeutics
UTHR
|
+$105M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$97.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Applied Materials
AMAT
|
+$238M |
| 2 |
DXC Technology
DXC
|
+$235M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$183M |
| 4 |
NXP Semiconductors
NXPI
|
+$158M |
| 5 |
Baidu
BIDU
|
+$154M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.57% |
| 2 | Healthcare | 20.55% |
| 3 | Consumer Discretionary | 12.58% |
| 4 | Financials | 7.32% |
| 5 | Communication Services | 6.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PRMW
676
DELISTED
Primo Water Corporation
PRMW
| $3.34M | 0.02% |
+199,804
| New | +$3.38M |
|
677
Edgewell Personal Care
EPC
$1.31B
| $3.31M | 0.01% |
+75,487
| New | +$3.2M |
|
678
Kymera Therapeutics
KYMR
$9.91B
| $3.28M | 0.01% |
+67,600
| New | +$2.93M |
|
679
Spyre Therapeutics
SYRE
$9.42B
| $3.27M | 0.01% |
18,791
-41,209
| -69% | -$7.49M |
|
680
Fresenius Medical Care
FMS
$12.5B
| $3.23M | 0.01% |
+77,800
| New | +$3.11M |
|
681
Harmony Biosciences
HRMY
$2.25B
| $3.22M | 0.01% |
+114,212
| New | +$3.43M |
|
|
LITS
682
Lite Strategy Inc
LITS
$35.4M
| $3.09M | 0.01% |
54,150
-3,360
| -6% | -$216K |
|
|
CAN
683
Canaan Creative
CAN
$272M
| $3.08M | 0.01% |
378,000
+275,900
| +270% | +$3.13M |
|
684
Omnicom Group
OMC
$24.4B
| $3.04M | 0.01% |
37,950
-288,110
| -88% | -$23.4M |
|
685
Arbutus Biopharma
ABUS
$1.04B
| $3.03M | 0.01% |
1,000,000
-37,700
| -4% | -$117K |
|
|
GRSV
686
DELISTED
Gores Holdings V, Inc.
GRSV
| $3.03M | 0.01% |
300,000
| – | – |
|
687
AEye
LIDR
$57.6M
| $3.01M | 0.01% |
10,000
| – | – |
|
|
VLTA
688
DELISTED
Volta Inc.
VLTA
| $3.01M | 0.01% |
300,000
| – | – |
|
689
AC Immune
ACIU
$286M
| $2.99M | 0.01% |
+376,600
| New | +$2.6M |
|
690
ScottsMiracle-Gro
SMG
$3.51B
| $2.94M | 0.01% |
15,324
-35,897
| -70% | -$7.92M |
|
691
Immunocore
IMCR
$1.89B
| $2.85M | 0.01% |
+72,900
| New | +$2.81M |
|
|
BNFT
692
DELISTED
Benefitfocus, Inc.
BNFT
| $2.84M | 0.01% |
+201,147
| New | +$2.84M |
|
693
Mercury Systems
MRCY
$5.36B
| $2.8M | 0.01% |
42,300
-15,600
| -27% | -$1.08M |
|
694
Signet Jewelers
SIG
$3.25B
| $2.76M | 0.01% |
34,200
-312,000
| -90% | -$20.2M |
|
|
RMGB
695
DELISTED
RMG Acquisition Corp. II Class A Ordinary Shares
RMGB
| $2.74M | 0.01% |
275,000
| – | – |
|
696
Generac Holdings
GNRC
$11.9B
| $2.73M | 0.01% |
+6,581
| New | +$2.21M |
|
697
Zymeworks
ZYME
$2.01B
| $2.72M | 0.01% |
78,300
-80,300
| -51% | -$2.55M |
|
698
Petco
WOOF
$834M
| $2.71M | 0.01% |
+120,900
| New | +$2.83M |
|
699
PubMatic
PUBM
$757M
| $2.67M | 0.01% |
+68,397
| New | +$2.85M |
|
|
PDAC
700
DELISTED
Peridot Acquisition Corp.
PDAC
| $2.66M | 0.01% |
218,577
+193,577
| +774% | +$2.08M |
|
Similar funds
Steven Cohen's Q2 2021 Portfolio in Review
As of Q2 2021, Steven Cohen held 1,274 positions worth $22.3B, up 4% from $21.4B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Steven Cohen's Q2 2021 filing shows 347 new, 260 increased, 248 reduced and 334 closed positions. Its largest new stake was United Therapeutics: 552,400 shares worth $99.1M. The largest sale was Applied Materials, an estimated $238M.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 22% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Steven Cohen's largest Q2 2021 buy was United Therapeutics: 552,400 shares worth $99.1M.
- Steven Cohen added most to Salesforce in Q2 2021, an estimated $372M increase.
- Steven Cohen's biggest Q2 2021 reduction was Applied Materials, cutting an estimated $238M.
- Steven Cohen fully exited DXC Technology in Q2 2021, selling an estimated $235M.
- Steven Cohen's ten largest holdings make up 18% of its $22.3B portfolio in Q2 2021.
- Steven Cohen opened 347 new positions and closed 334 in Q2 2021.
- Steven Cohen's portfolio value rose 4% quarter-over-quarter to $22.3B.
Based on Point72 Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.